Search Results for "Invokamet"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Invokamet. Results 1 to 3 of 3 total matches.

In Brief: Canagliflozin and Lower Limb Amputations

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2020  (Issue 1607)
, Invokamet, Invokamet XR) that described an increased risk of lower limb amputation associated with use ...
The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Invokamet, Invokamet XR) that described an increased risk of lower limb amputation associated with use of the drug. Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):152 |  Show IntroductionHide Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
; HFrEF = heart failure with reduced ejection fraction Invokana Invokamet Glyxambi Forxiga Farxiga ...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8 |  Show IntroductionHide Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
Invokamet 500/50, 1000/50, 500/150, 500/50-500/150 mg PO bid4,39 570.10 (Janssen) 1000/150 mg tabs ...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 |  Show IntroductionHide Introduction